genome transcription hotspot technology

CHO Plus was founded in 2014 to address the high costs and capacity issues facing therapeutic protein manufacturers. It has developed patented technology for creating highly productive, GMP-compliant mammalian cell lines used for the production of therapeutic proteins and viruses, demonstrating a 10-fold protein productivity increase versus parent cells in a model system. The company plans to license its technology to and collect royalties from biopharmaceutical companies.

Read more

cell engineeringmammalian cell line developmenttechnology licensing